CStone Pharmaceuticals
PH4
Company Profile
Business description
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
Contact
218 Xinghu Street
C1 Building, North Block
Suzhou Industrial Park
Suzhou215123
CHNT: +86 51287186550
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
136
Stocks News & Analysis
stocks
ASX share undervalued despite margin woes
Short term margin pressure yet shares remain undervalued on improved outlook.
stocks
A better way to predict long-term stock returns
A value-weighted version of the CAPE ratio corrects a structural flaw and delivers stronger forecasts of long-term stock returns.
stocks
Five star stock added to August best ideas list
Morningstar analysts hand pick this undervalued opportunity for their August global best ideas.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,853.30 | 70.60 | -0.79% |
| CAC 40 | 8,117.78 | 61.99 | -0.76% |
| DAX 40 | 25,440.81 | 127.75 | -0.50% |
| Dow JONES (US) | 52,421.20 | 152.09 | -0.29% |
| FTSE 100 | 10,697.57 | 47.13 | 0.44% |
| HKSE | 24,818.06 | 99.54 | -0.40% |
| NASDAQ | 26,186.41 | 146.62 | -0.56% |
| Nikkei 225 | 64,004.66 | 511.67 | 0.81% |
| NZX 50 Index | 13,495.27 | 65.42 | -0.48% |
| S&P 500 | 7,619.98 | 37.00 | -0.48% |
| S&P/ASX 200 | 8,671.70 | 78.20 | -0.89% |
| SSE Composite Index | 3,883.24 | 2.10 | -0.05% |